Prevalence and Prognostic Significance of Hyponatremia in Patients With Lung Cancer: Systematic Review and Meta-Analysis

Frontiers in Medicine

Mária Földi¹  Szabolcs Kiss¹  László Bajnok²  Emese Mezösi²  Marin Gergics²  Péter Hegyi⁴  Margit Solymár⁴  Benedek Tinusz⁴  Zsolt Szakács⁴  Dávid Németh⁴  Eszter Bartalis⁵ 

[1] Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary;First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary;Medical School, Institute for Translational Medicine, University of Pécs, Pécs, Hungary;Szentágothai Research Centre, University of Pécs, Pécs, Hungary;University of Medicine, Pharmacy, Science and Technology of Târgu Mureş, Târgu Mureş, Romania;

关键词: lung cancer;    NSCLC;    SCLC;    hyponatremia;    SIADH;   

DOI  :  10.3389/fmed.2021.671951

来源: DOAJ

【 摘 要 】

Background: The prevalence of hyponatremia is highly variable among patients with lung cancer. However, its prevalence and prognostic significance in subgroups of patients with lung cancer have not yet been evaluated in a meta-analysis.Methods: We have registered our meta-analysis and review protocol to the PROSPERO International Prospective Register of Systematic Reviews, with the following registration number: CRD42020167013. A systematic search was done in the following sources: MEDLINE, Embase, CENTRAL, Web of Science, ClinicalTrials.gov, a WHO Global Health Library.Results: We identified a total of 8,962 potentially eligible studies, and we included 31 articles in our evaluation. The prevalence of hyponatremia in patients with lung cancer varied between 3 and 94.8% with an average of 25% without any significant differences between the following subgroups: histotype, gender, age, Eastern Cooperative Oncology Group (ECOG) state, and the extent of disease. The overall survival (OS) was significantly lower in hyponatremic compared to normonatremic patients at 10 months [RR.59 (95% CI.47–0.74), p < 0.001] and at 20 months [RR.44 (95% CI.33–0.59), p < 0.001], with worse survival rates in non-small cell lung cancer (NSCLC) [RR.27 (95% CI.12–0.44), p < 0.001] than in small cell lung cancer (SCLC) [RR.42 (95% CI.27–0.57), p < 0.001]. If hyponatremia was corrected, OS at 10 months was significantly higher than in the uncorrected hyponatremia group [RR 1.83 (95% CI 1.37–2.44), p < 0.001], but, at 20 months, no statistically significant difference could be found between these subgroups [RR 2.65 (95% CI.94–7.50), p = 0.067].Conclusions: Patients with lung cancer diagnosed with hyponatremia, especially patients with NSCLC, seem to have significantly lower survival rates than normonatremic patients. If hyponatremia remains uncorrected, the mortality rates might be even higher.

【 授权许可】

Unknown